PROCEPT BioRobotics Corp. Announces Investor Event at 2023 AUA Annual Meeting in Chicago
31 3월 2023 - 5:05AM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the
“Company”), a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology,
announced today it will host an in-person investor event on Friday,
April 28, 2023, in Chicago at the American Urological Association
Annual Meeting from 8:00am to 9:30am Central Time. This meeting
will be held at the Gwen Hotel and will include remarks from
PROCEPT BioRobotics’ executive team, in addition to a surgeon panel
on the benefits of Aquablation therapy.
Members of PROCEPT BioRobotics’ management team presenting
include:
- Reza Zadno – President & Chief
Executive Officer
- Kevin Waters – Executive VP & Chief
Financial Officer
- Sham Shiblaq – Executive VP & Chief
Commercial Officer
- Barry Templin – Senior VP, Clinical &
Medical Affairs
Clinical perspectives will also be provided by the following
physicians:
- Dr. Dean Elterman, Division of Urology,
Toronto Western Hospital, University of Toronto
- Dr. Brian Helfand, Division of Urology,
NorthShore University Health System
- Dr. Jonathan Pavlinec, Florida Urology
Partners, South Bay Hospital – HCA West Florida Division
A live webcast of the event, as well as an archived recording,
will be available on the “Investors” section of the Company’s
website at https://ir.procept-biorobotics.com/. The webcast will be
archived and available for replay for at least 90 days after the
event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 150 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Important Safety Information
All surgical treatments have inherent and associated side
effects. For a list of potential side effects
visit https://aquablation.com/safety-information/.
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024